246 related articles for article (PubMed ID: 36502695)
1. Development of an automated combined positive score prediction pipeline using artificial intelligence on multiplexed immunofluorescence images.
Vahadane A; Sharma S; Mandal D; Dabbeeru M; Jakthong J; Garcia-Guzman M; Majumdar S; Lee CW
Comput Biol Med; 2023 Jan; 152():106337. PubMed ID: 36502695
[TBL] [Abstract][Full Text] [Related]
2. An artificial intelligence-powered PD-L1 combined positive score (CPS) analyser in urothelial carcinoma alleviating interobserver and intersite variability.
Lee KS; Choi E; Cho SI; Park S; Ryu J; Puche AV; Ma M; Park J; Jung W; Ro J; Kim S; Park G; Song S; Ock CY; Choe G; Park JH
Histopathology; 2024 Jul; 85(1):81-91. PubMed ID: 38477366
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous cell carcinoma.
Liu Z; Williams M; Stewart J; Glisson BS; Fuller C; Roy-Chowdhuri S
Cancer Cytopathol; 2022 Feb; 130(2):110-119. PubMed ID: 34375025
[TBL] [Abstract][Full Text] [Related]
4. Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy.
Yeong J; Lum HYJ; Teo CB; Tan BKJ; Chan YH; Tay RYK; Choo JR; Jeyasekharan AD; Miow QH; Loo LH; Yong WP; Sundar R
Gastric Cancer; 2022 Jul; 25(4):741-750. PubMed ID: 35661944
[TBL] [Abstract][Full Text] [Related]
5. Analysis of Immunological Characteristics and Genomic Alterations in HPV-Positive Oropharyngeal Squamous Cell Carcinoma Based on PD-L1 Expression.
Xu SM; Shi CJ; Xia RH; Wang LZ; Tian Z; Ye WM; Liu L; Liu SL; Zhang CY; Hu YH; Zhou R; Han Y; Wang Y; Zhang ZY; Li J
Front Immunol; 2021; 12():798424. PubMed ID: 35145511
[TBL] [Abstract][Full Text] [Related]
6. A Pipeline for Evaluation of Machine Learning/Artificial Intelligence Models to Quantify Programmed Death Ligand 1 Immunohistochemistry.
Knudsen BS; Jadhav A; Perry LJ; Thagaard J; Deftereos G; Ying J; Brintz BJ; Zhang W
Lab Invest; 2024 Jun; 104(6):102070. PubMed ID: 38677590
[TBL] [Abstract][Full Text] [Related]
7. Multiplex immunofluorescence to measure dynamic changes in tumor-infiltrating lymphocytes and PD-L1 in early-stage breast cancer.
Sanchez K; Kim I; Chun B; Pucilowska J; Redmond WL; Urba WJ; Martel M; Wu Y; Campbell M; Sun Z; Grunkemeier G; Chang SC; Bernard B; Page DB
Breast Cancer Res; 2021 Jan; 23(1):2. PubMed ID: 33413574
[TBL] [Abstract][Full Text] [Related]
8. Validation of multiplex immunofluorescence and digital image analysis for programmed death-ligand 1 expression and immune cell assessment in non-small cell lung cancer: comparison with conventional immunohistochemistry.
Wu J; Mao L; Sun W; Yang X; Wang H; Liu X; Chi K; Huang X; Lin D
J Clin Pathol; 2022 Jul; 75(7):452-458. PubMed ID: 33782193
[TBL] [Abstract][Full Text] [Related]
9. The clinicopathological significance of PD-L1 expression assessed by the combined positive score (CPS) in head and neck squamous cell carcinoma.
Wusiman D; Guo L; Huang Z; Li Z; Liu S; Ying J; Li W; An C
Pathol Res Pract; 2022 Aug; 236():153934. PubMed ID: 35691098
[TBL] [Abstract][Full Text] [Related]
10. Spatial Intratumoral Heterogeneity Expression of PD-L1 Antigen in Head and Neck Squamous Cell Carcinoma.
Hirshoren N; Al-Kharouf I; Weinberger JM; Eliashar R; Popovtzer A; Knaanie A; Fellig Y; Neuman T; Meir K; Maly A; Vainer GW
Oncology; 2021; 99(7):464-470. PubMed ID: 33789303
[TBL] [Abstract][Full Text] [Related]
11. Association of artificial intelligence-powered and manual quantification of programmed death-ligand 1 (PD-L1) expression with outcomes in patients treated with nivolumab ± ipilimumab.
Baxi V; Lee G; Duan C; Pandya D; Cohen DN; Edwards R; Chang H; Li J; Elliott H; Pokkalla H; Glass B; Agrawal N; Lahiri A; Wang D; Khosla A; Wapinski I; Beck A; Montalto M
Mod Pathol; 2022 Nov; 35(11):1529-1539. PubMed ID: 35840720
[TBL] [Abstract][Full Text] [Related]
12. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
[TBL] [Abstract][Full Text] [Related]
13. Multidimensional immune profiling in Gastric Cancer Multiplex Immunohistochemistry Atlas from Peking University Cancer Hospital project informs PD-1/PD-L1 blockade efficacy.
Jia K; Chen Y; Xie Y; Chong X; Li Y; Wu Y; Yuan J; Li Y; Feng X; Hu Y; Sun Y; Gong J; Zhang X; Li J; Shen L
Eur J Cancer; 2023 Aug; 189():112931. PubMed ID: 37343324
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 expression in bladder cancer: Which scoring algorithm in what tissue?
Schulz GB; Todorova R; Braunschweig T; Rodler S; Volz Y; Eismann L; Pfitzinger P; Jokisch F; Buchner A; Stief C; Mayr D; Casuscelli J
Urol Oncol; 2021 Oct; 39(10):734.e1-734.e10. PubMed ID: 34261585
[TBL] [Abstract][Full Text] [Related]
15. Evaluating programmed death-ligand 1 (PD-L1) in head and neck squamous cell carcinoma: concordance between the 22C3 PharmDx assay and the SP263 assay on whole sections from a multicentre study.
Cerbelli B; Girolami I; Eccher A; Costarelli L; Taccogna S; Scialpi R; Benevolo M; Lucante T; Luigi Alò P; Stella F; Gemma Pignataro M; Fadda G; Perrone G; D'Amati G; Martini M
Histopathology; 2022 Jan; 80(2):397-406. PubMed ID: 34496080
[TBL] [Abstract][Full Text] [Related]
16. Determining PD-L1 expression in head and neck squamous cell carcinoma using immunohistochemistry.
Mishra PS; Sidhu A; Dwivedi G; Mulajker DS; Awasthi S
Indian J Cancer; 2022; 59(4):474-479. PubMed ID: 33753620
[TBL] [Abstract][Full Text] [Related]
17. Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images.
Mu W; Jiang L; Shi Y; Tunali I; Gray JE; Katsoulakis E; Tian J; Gillies RJ; Schabath MB
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34135101
[TBL] [Abstract][Full Text] [Related]
18. High Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma.
Robert ME; Rüschoff J; Jasani B; Graham RP; Badve SS; Rodriguez-Justo M; Kodach LL; Srivastava A; Wang HL; Tang LH; Troncone G; Rojo F; Van Treeck BJ; Pratt J; Shnitsa I; Kumar G; Karasarides M; Anders RA
Mod Pathol; 2023 May; 36(5):100154. PubMed ID: 36925069
[TBL] [Abstract][Full Text] [Related]
19. Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy.
Althammer S; Tan TH; Spitzmüller A; Rognoni L; Wiestler T; Herz T; Widmaier M; Rebelatto MC; Kaplon H; Damotte D; Alifano M; Hammond SA; Dieu-Nosjean MC; Ranade K; Schmidt G; Higgs BW; Steele KE
J Immunother Cancer; 2019 May; 7(1):121. PubMed ID: 31060602
[TBL] [Abstract][Full Text] [Related]
20. Predicting EGFR and PD-L1 Status in NSCLC Patients Using Multitask AI System Based on CT Images.
Wang C; Ma J; Shao J; Zhang S; Liu Z; Yu Y; Li W
Front Immunol; 2022; 13():813072. PubMed ID: 35250988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
